- Home
- JSPR vs DCTH Comparison
JSPR vs DCTH Comparison
Compare JSPR & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- DCTH
- Stock Information
- Founded
- JSPR 2018
- DCTH 1988
- Country
- JSPR United States
- DCTH United States
- Employees
- JSPR N/A
- DCTH N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- DCTH Medical/Dental Instruments
- Sector
- JSPR Health Care
- DCTH Health Care
- Exchange
- JSPR Nasdaq
- DCTH Nasdaq
- Market Cap
- JSPR 85.8M
- DCTH 426.3M
- IPO Year
- JSPR N/A
- DCTH N/A
- Fundamental
- Price
- JSPR $3.31
- DCTH $11.03
- Analyst Decision
- JSPR Buy
- DCTH Strong Buy
- Analyst Count
- JSPR 12
- DCTH 4
- Target Price
- JSPR $31.67
- DCTH $24.00
- AVG Volume (30 Days)
- JSPR 1.4M
- DCTH 898.0K
- Earning Date
- JSPR 08-12-2025
- DCTH 08-04-2025
- Dividend Yield
- JSPR N/A
- DCTH N/A
- EPS Growth
- JSPR N/A
- DCTH N/A
- EPS
- JSPR N/A
- DCTH N/A
- Revenue
- JSPR N/A
- DCTH $53,850,000.00
- Revenue This Year
- JSPR N/A
- DCTH $162.10
- Revenue Next Year
- JSPR N/A
- DCTH $32.97
- P/E Ratio
- JSPR N/A
- DCTH N/A
- Revenue Growth
- JSPR N/A
- DCTH 1068.87
- 52 Week Low
- JSPR $2.27
- DCTH $7.17
- 52 Week High
- JSPR $26.05
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- JSPR 34.76
- DCTH 34.31
- Support Level
- JSPR $2.71
- DCTH $11.20
- Resistance Level
- JSPR $4.00
- DCTH $12.72
- Average True Range (ATR)
- JSPR 0.60
- DCTH 0.58
- MACD
- JSPR -0.25
- DCTH -0.12
- Stochastic Oscillator
- JSPR 21.22
- DCTH 22.18
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.